The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older
Open accessAbstract
BACKGROUND: A trial involving adults 50 years of age or older (ZOE-50) showed that the herpes zoster subunit vaccine (HZ/su) containing recombinant varicella-zoster virus glycoprotein E and the AS01B adjuvant system was associated with a risk of herpes zoster that was 97.2% lower than that associated with placebo. A second trial was performed concurrently at the same sites and examined the safety and efficacy of HZ/su in adults 70 years of age or older (ZOE-70). METHODS: This randomized, placebo-controlled, phase 3 trial was conducted in 18 countries and involved adults 70 years of age or older. Participants received two doses of HZ/su or placebo (assigned in a 1:1 ratio) administered intramuscularly 2 months apart. Vaccine efficacy against herpes zoster and postherpetic neuralgia was assessed in participants from ZOE-70 and in participants pooled from ZOE-70 and ZOE-50. RESULTS: In ZOE-70, 13,900 participants who could be evaluated (mean age, 75.6 years) received either HZ/su (6950 participants) or placebo (6950 participants). During a mean follow-up period of 3.7 years, herpes zoster occurred in 23 HZ/su recipients and in 223 placebo recipients (0.9 vs. 9.2 per 1000 person-years). Vaccine efficacy against herpes zoster was 89.8% (95% confidence interval [CI], 84.2 to 93.7; P<0.001) and was similar in participants 70 to 79 years of age (90.0%) and participants 80 years of age or older (89.1%). In pooled analyses of data from participants 70 years of age or older in ZOE-50 and ZOE-70 (16,596 participants), vaccine efficacy against herpes zoster was 91.3% (95% CI, 86.8 to 94.5; P<0.001), and vaccine efficacy against postherpetic neuralgia was 88.8% (95% CI, 68.7 to 97.1; P<0.001). Solicited reports of injection-site and systemic reactions within 7 days after injection were more frequent among HZ/su recipients than among placebo recipients (79.0% vs. 29.5%). Serious adverse events, potential immune-mediated diseases, and deaths occurred with similar frequencies in the two study groups. CONCLUSIONS: In our trial, HZ/su was found to reduce the risks of herpes zoster and postherpetic neuralgia among adults 70 years of age or older. (Funded by GlaxoSmithKline Biologicals; ZOE-50 and ZOE-70 ClinicalTrials.gov numbers, NCT01165177 and NCT01165229 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The degree of reactogenicity after one dose of mRNA-1273 was less than that observed for the recently approved recombinant adjuvanted zoster vaccine and after the second mRNA-1273 dose was similar to that of the zoster vaccine. 21,22”
From Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine (2021) · cites this paper as [21]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Vaccination against VZV is considered an effective approach to reduce the risk of shingles32.”
From Algorithm for optimized mRNA design improves stability and immunogenicity (2023) · cites this paper as [32]
In the citing paper
“the AS01B-adjuvanted VZV gE subunit vaccine was highly effective irrespective of age”
From Successful and Maladaptive T Cell Aging (2017) · cites this paper as Cunningham et al., 2016
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The burden of disease in older people and implications for health policy and practice
Prince, M. J., Wu, F., Guo, Y., Gutiérrez‐Robledo, L. M., O'Donnell, M. J., Sullivan, R. J., & Yusuf, S. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61347-7 · Cited by 2,473
A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults
Oxman, M. N., Levin, M. J., Johnson, G. R., Schmader, K. E., Straus, S. E., Gelb, L. D., Arbeit, R. D., Simberkoff, M. S., Gershon, A. A., Davis, L. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051016 · Cited by 2,412
Self-citationEfficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults
Lal, H., Cunningham, A. L., Godeaux, O., Chlibek, R., Diez-Domingo, J., Hwang, S.-J., Levin, M. J., McElhaney, J. E., Poder, A., Puig-Barberà, J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501184 · Cited by 1,454
Self-citationSystematic review of incidence and complications of herpes zoster: towards a global perspective
Kawai, K., Gebremeskel, B. G., & Acosta, C. J. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-004833 · Cited by 943
Yawn, B. P., Saddier, P., Wollan, P. C., Sauver, J. L. S., Kurland, M. J., & Sy, L. S. (2007) · Mayo Clinic Proceedings · doi:10.4065/82.11.1341 · Cited by 866
A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants
The RTS, S. C. T. P. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208394 · Cited by 752
Cohen, J. I. (2013) · New England Journal of Medicine · doi:10.1056/nejmcp1302674 · Cited by 737
Johnson, R. W., & Rice, A. S. C. (2014) · New England Journal of Medicine · doi:10.1056/nejmcp1403062 · Cited by 575
The incidence of herpes zoster in a United States administrative database
Insinga, R. P., Itzler, R. F., Pellissier, J. M., Saddier, P., & Nikas, A. A. (2005) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2005.0150.x · Cited by 490
Recent clinical experience with vaccines using MPL- and QS-21-containing Adjuvant Systems
Garçon, N., & Mechelen, M. V. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.29 · Cited by 318
Research works printed but not linked: 3
- Harpaz R, 2008, MMWR Recomm Rep, 57, 1
- Chen N, 2014, Cochrane Database Syst Rev, CD006866
- 2011, MMWR Morb Mortal Wkly Rep, 60, 1528
Cited by
Sorted by citations
Items 301–400 of 1,000
Recent topics in the management of herpes zoster
Asada, H. (2022) · The Journal of Dermatology · doi:10.1111/1346-8138.16666 · Cited by 23
STING-activating layered double hydroxide nano-adjuvants for enhanced cancer immunotherapy
Jia, L., Yang, Q., Li, X., Liu, H., He, Z., & Wang, Y. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123294 · Cited by 23
Adjuvanted Recombinant Glycoprotein E Herpes Zoster Vaccine
Levin, M. J., & Weinberg, A. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz770 · Cited by 23
Self-citationAssociation of herpes zoster and chronic inflammatory skin disease in US inpatients
Chovatiya, R., & Silverberg, J. I. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.12.073 · Cited by 23
Dagnew, A. F., Klein, N. P., Hervé, C., Kalema, G., Paolo, E. D., Peterson, J., Salaun, B., & Schuind, A. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa083 · Cited by 23
Cao, H., Wang, Y., Luan, N., & Liu, C. (2021) · Vaccines · doi:10.3390/vaccines9040310 · Cited by 23
Winthrop, K. L., Tanaka, Y., Lee, E. B., Wollenhaupt, J., Alenizi, A., Azevedo, V. F., & Curtis, J. R. (2022) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/cpu6r9 · Cited by 23
A glimpse into the future of systemic lupus erythematosus
Aringer, M., Alarcón-Riquelme, M. E., Clowse, M. E. B., Pons-Estel, G. J., Vital, E. M. J., & Dall’Era, M. (2022) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x221086719 · Cited by 23
Ferreiro‐Iglesias, R., Piqueras, M., Ricart, E., Sempere, L., Roca, M., de Carpi, J. M., Benítez, O., Zabana, Y., Mañosa, M., Rodríguez‐Moranta, F., et al. (2022) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2022.03.012 · Cited by 23
Kunzler, A. L. F., & Tsokos, G. C. (2023) · European Journal of Rheumatology · doi:10.5152/eurjrheum.2023.23068 · Cited by 23
Herpes zoster in the context of varicella vaccination – An equation with several variables
Wutzler, P., Casabona, G., Cnops, J., Akpo, E. I. H., & Sáfadi, M. A. P. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.09.013 · Cited by 23
The Prevention of Infections in Older Adults: Vaccination
Coll, P. P., Costello, V. W., Kuchel, G. A., Bartley, J. M., & McElhaney, J. E. (2019) · Journal of the American Geriatrics Society · doi:10.1111/jgs.16205 · Cited by 22
Self-citationKonzett, V., Smolen, J. S., Nash, P. T., Winthrop, K. L., Aletaha, D., Dörner, T., Fleischmann, R., Tanaka, Y., Primdahl, J., Baraliakos, X., et al. (2025) · Annals of the Rheumatic Diseases · doi:10.1016/j.ard.2025.01.024 · Cited by 22
Assessing and Improving Zoster Vaccine Uptake in a Homeless Population
Kaplan-Weisman, L., Waltermaurer, E., & Crump, C. (2018) · Journal of Community Health · doi:10.1007/s10900-018-0517-x · Cited by 22
Oorschot, D. V., Hunjan, M., Bracke, B., Lorenc, S., Curran, D., & Camejo, H. S. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-025553 · Cited by 22
Andrews, N. J., Stowe, J., Kuyumdzhieva, G., Sile, B., Yonova, I., de Lusignan, S., Ramsay, M. E., & Amirthalingam, G. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-037458 · Cited by 22
Effects of Varicella-Zoster Virus Glycoprotein E Carboxyl-Terminal Mutation on mRNA Vaccine Efficacy
Cao, H., Wang, Y., Luan, N., Lin, K., & Liu, C. (2021) · Vaccines · doi:10.3390/vaccines9121440 · Cited by 23
Safety of Recombinant Zoster Vaccine in Patients with Inflammatory Bowel Disease
Khan, N. H., Trivedi, C. P., Aberra, F. N., Pernes, T., & Yang, Y. (2022) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjac040 · Cited by 22
Immunosenescence, Immune Fitness and Vaccination Schedule in the Adult Respiratory Patient
Álvarez, F. V., de la Rosa, D., Fariñas-Guerrero, F., & Jimenez-Ruiz, C. A. (2022) · Open Respiratory Archives · doi:10.1016/j.opresp.2022.100181 · Cited by 23
Breznik, J. A., Huynh, A., Zhang, A., Bilaver, L., Bhakta, H., Stacey, H. D., Ang, J. C., Bramson, J. L., Nazy, I., Miller, M. S., et al. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2200369 · Cited by 23
Laing, K. J., Ford, E. S., Johnson, M. J., Levin, M. J., Koelle, D. M., & Weinberg, A. (2023) · Journal of Clinical Investigation · doi:10.1172/jci172634 · Cited by 22
Self-citationVaricella Virus Vaccination in the United States
Shaw, J., & Gershon, A. A. (2017) · Viral Immunology · doi:10.1089/vim.2017.0136 · Cited by 22
Watanabe, D., Mizukami, A., Holl, K., Curran, D., Oorschot, D. V., Varghese, L., & Shiragami, M. (2018) · Dermatology and Therapy · doi:10.1007/s13555-018-0236-3 · Cited by 22
Self-citationCost-effectiveness of the recombinant zoster vaccine in the German population aged ≥60 years old
Oorschot, D. V., Anastassopoulou, A., Nautrup, B. P., Varghese, L., von Krempelhuber, A., Neine, M. E. M., Lorenc, S., & Curran, D. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1509645 · Cited by 22
Nanotoxoids: Biomimetic Nanoparticle Vaccines against Infections
Guo, Z., Kubiatowicz, L. J., Fang, R. H., & Zhang, L. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202100072 · Cited by 22
Siedler, A., Koch, J., Garbe, E., Hengel, H., von Kries, R., Ledig, T., Mertens, T., Zepp, F., & Überla, K. (2019) · PubMed · doi:10.1007/s00103-019-02882-5 · Cited by 21
Curtis, J. R., Conrad, D. M., Krueger, W. S., Gara, A., & Winthrop, K. L. (2025) · Arthritis Research & Therapy · doi:10.1186/s13075-025-03565-0 · Cited by 21
Johnson, M. J., Liu, C., Ghosh, D., Lang, N., Levin, M. J., & Weinberg, A. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab580 · Cited by 21
Self-citationYawn, B. P., Merrill, D. D., Martinez, S., Callen, E. F., COTTON, J., Williams, D. M., & Loskutova, N. (2022) · Vaccines · doi:10.3390/vaccines10030420 · Cited by 21
Insights into the Novel Therapeutics and Vaccines against Herpes Simplex Virus
Malik, S., Sah, R., Ahsan, O., Muhammad, K., & Waheed, Y. (2023) · Vaccines · doi:10.3390/vaccines11020325 · Cited by 21
Silverii, G. A., Clerico, A., Fornengo, R., Gabutti, G., Sordi, V., Peruzzi, O., Tafuri, S., Mannucci, E., & Dicembrini, I. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02127-7 · Cited by 52
Vaccine Development for Varicella-Zoster Virus
Sadaoka, T., & Mori, Y. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-7230-7_7 · Cited by 20
de Boer, P. T., van Lier, A., de Melker, H. E., van Wijck, A. J. M., Wilschut, J., van Hoek, A. J., & Postma, M. J. (2018) · BMC Medicine · doi:10.1186/s12916-018-1213-5 · Cited by 21
MacIntyre, C. R., Ridda, I., Trent, M. J., & McIntyre, P. B. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.07.005 · Cited by 21
Innate immune cell activation by adjuvant AS01 in human lymph node explants is age independent
Stylianou, V. V., Bertram, K. M., Vo, V. A., Dunn, E. B., Baharlou, H., Terre, D. D., Elhindi, J., Elder, E. E., French, J. R., Meybodi, F., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci174144 · Cited by 23
Self-citationAssociation Between the Risk for Cardiovascular Events and Antiviral Treatment for Herpes Zoster
Kim, J., Jeon, J., Lee, H. S., & Lee, K. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1384 · Cited by 20
Dagnew, A. F., Vink, P., Dramé, M., Willer, D. O., Salaun, B., & Schuind, A. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1930846 · Cited by 20
Lee, C., Jiang, N., Tang, H., Ye, C., Yuan, Y., & Curran, D. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1932216 · Cited by 20
Management of Adverse Events and Supportive Therapy in Relapsed/Refractory Multiple Myeloma
Pozzi, S., Bari, A., Pecherstorfer, M., & Vallet, S. (2021) · Cancers · doi:10.3390/cancers13194978 · Cited by 20
Min, J.-Y., Mwakingwe-Omari, A., Riley, M. E., Molo, L. Y., Soni, J., Girard, G., & Danier, J. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.12.033 · Cited by 20
Teng, L., Mizukami, A., Ng, C., Giannelos, N., Curran, D., Sato, T., Lee, C., & Matsuki, T. (2022) · Dermatology and Therapy · doi:10.1007/s13555-022-00744-8 · Cited by 20
Creech, C. B., Frenck, R. W., Fiquet, A., Feldman, R., Kankam, M. K., Pathirana, S., Baber, J., Radley, D. R., Cooper, D., Eiden, J., et al. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofz532 · Cited by 20
Hong, H., Kim, K. S., Park, S. A., Chun, M. J., Hong, E. Y., Chung, S. W., Kim, H. J., Shin, B. G., Braka, A., Thanappan, J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.22.436375 · Cited by 20
Harshbarger, W. D., Holzapfel, G. A., Seraj, N., Tian, S., Chesterman, C. C., Fu, Z., Pan, Y., Harelson, C., Peng, D.-J., Huang, Y., et al. (2024) · Vaccines · doi:10.3390/vaccines12101111 · Cited by 19
Rayens, E. A., Sy, L. S., Qian, L., Wu, J., Ackerson, B. K., Luo, Y., Zheng, C., Cheng, Y., Daily, L. I. V., Song, J., et al. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf440 · Cited by 19
Park, S. Y., Levin, M. J., Canniff, J. D., Johnson, M. J., Schmid, D. S., & Weinberg, A. (2022) · npj Vaccines · doi:10.1038/s41541-022-00545-2 · Cited by 19
Self-citationImmunogenicity and Efficacy of Vaccination in People Living with Human Immunodeficiency Virus
Tortellini, E., Ngangue, Y. C. F., Dominelli, F., Guardiani, M., Falvino, C., Mengoni, F., Carraro, A., Marocco, R., Pasculli, P., Mastroianni, C. M., et al. (2023) · Viruses · doi:10.3390/v15091844 · Cited by 24
Losa, L., Antonazzo, I. C., Martino, G. D., Mazzaglia, G., Tafuri, S., Mantovani, L. G., & Ferrara, P. (2024) · Vaccines · doi:10.3390/vaccines12050527 · Cited by 19
Vaccines for the Elderly and Vaccination Programs in Europe and the United States
Anastassopoulou, C. G., Ferous, S., Medić, S., Siafakas, N., Boufidou, F., Gioula, G., & Tsakris, A. (2024) · Vaccines · doi:10.3390/vaccines12060566 · Cited by 21
Ogawa, Y., Takei, H., Ogawa, R., & Mihara, K. (2017) · Journal of Pharmaceutical Health Care and Sciences · doi:10.1186/s40780-017-0087-6 · Cited by 19
Nanomedicine to deliver biological macromolecules for treating COVID-19
Wilson, B., & Geetha, K. M. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.05.068 · Cited by 18
Mathian, A., Pha, M., & Amoura, Z. (2018) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000525 · Cited by 19
Kornelius, E., Lo, S., Huang, C., Wang, C., Wang, Y., & Yang, Y. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-090428 · Cited by 18
Patterson, B. J., Myers, K., Stewart, A., Mange, B., Hillson, E., & Poulos, C. M. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1910502 · Cited by 18
Liu, D., Chen, J., Fang, Z.-Z., Liu, S., & Wan, L. (2021) · Pain Research and Management · doi:10.1155/2021/6638392 · Cited by 18
Patterson, B. J., Chen, C., McGuiness, C. B., Ma, S., Glasser, L., Sun, K., & Buck, P. O. (2021) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2021.11.010 · Cited by 18
Kim, J. H., Johnson, R. W., Kovac, M., Cunningham, A. L., Amakrane, M., Sullivan, K. M., Dagnew, A. F., Curran, D., & Schuind, A. (2022) · Pain · doi:10.1097/j.pain.0000000000002760 · Cited by 18
Self-citationPublic health impact of herpes zoster vaccination on older adults in Hong Kong
Chan, P. K. S., Wong, M. C. S., Chan, M., Ching, K., Giannelos, N., & Ng, C. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2176065 · Cited by 18
Age-dependent changes in T follicular helper cells shape the humoral immune response to vaccination
Linterman, M. A. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101801 · Cited by 17
Choi, W. S., Song, J. Y., Kwon, K. T., Lee, H.-J., Choo, E. J., Baek, J. H., Chin, B., Kim, W. J., Lee, M. S., Park, W. B., et al. (2024) · Infection and Chemotherapy · doi:10.3947/ic.2023.0072 · Cited by 19
Ishihara, R., Watanabe, R., Shiomi, M., Katsushima, M., Fukumoto, K., Yamada, S., Okano, T., & Hashimoto, M. (2024) · Biomolecules · doi:10.3390/biom14070739 · Cited by 18
Using Number Needed to Harm to Put the Risk of Herpes Zoster From Tofacitinib in Perspective
Caldera, F., Hayney, M. S., & Cross, R. K. (2019) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izy387 · Cited by 18
Bollaerts, K., Αλεξανδρίδου, Μ., & Verstraeten, T. (2019) · Vaccine X · doi:10.1016/j.jvacx.2019.100007 · Cited by 20
Schmader, K. E., Levin, M. J., Chen, M. J., Matthews, S., Riley, M. E., Woo, W., Hervé, C., Grupping, K., Schuind, A., Oostvogels, L., et al. (2020) · The Journals of Gerontology Series A · doi:10.1093/gerona/glaa127 · Cited by 18
Self-citationUnderstanding and improving vaccine efficacy in older adults
Hofer, S. J., Rapp, S., Klenerman, P., & Simon, A. K. (2025) · Nature Aging · doi:10.1038/s43587-025-00939-6 · Cited by 23
Lin, J., Dobbins, T., Wood, J., Bernardo, C., Stocks, N., & Liu, B. C. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.01.067 · Cited by 17
Curran, D., Patterson, B. J., Carrico, J., Salem, A., La, E. M., Lorenc, S., Hicks, K. A., Poston, S. A., & Carpenter, C. F. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2167907 · Cited by 17
Lin, K., Cao, H., Luan, N., Wang, Y., Hu, J., & Liu, C. (2023) · Vaccines · doi:10.3390/vaccines11051003 · Cited by 17
Kojima, S., Iwamoto, T., Kobayashi, Y., Kato, M., Takizawa, F., Ida, T., Suzuki, J., Toda, Y., Miyachi, K., Iwata, A., et al. (2024) · RMD Open · doi:10.1136/rmdopen-2023-003902 · Cited by 17
Bhattacharya, A., Lonzarić, J., Burlak, O., Li, J., Upadhyay, G., Williams, K., Dong, J., Rohrer, H., Pynn, M., Simon, A., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00865-5 · Cited by 21
Herpes zoster in hospitalized adults: Practice gaps, new evidence, and remaining questions
Ahronowitz, I. Z., & Fox, L. P. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.07.054 · Cited by 17
Shiragami, M., Mizukami, A., Kaise, T., Curran, D., Oorschot, D. V., Bracke, B., & Watanabe, D. (2019) · Dermatology and Therapy · doi:10.1007/s13555-019-0291-4 · Cited by 17
Self-citationHoshi, S., Seposo, X., Shono, A., Okubo, I., & Kondo, M. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.05.006 · Cited by 17
Volpi, A., Boccalini, S., Dari, S., Clarke, C., Curran, D., Loiacono, I., Pitrelli, A., Puggina, A., Tosatto, R., Oorschot, D. V., et al. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1657753 · Cited by 17
Precision immunization: a new trend in human vaccination
Jia, S., Li, J., Liu, Y., & Zhu, F. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1670123 · Cited by 16
Herpes zoster vaccination in Australia: what's available and who benefits?
Jayasinghe, S. H., Sheridan, S. L., & Macartney, K. K. (2020) · Australian Prescriber · doi:10.18773/austprescr.2020.001 · Cited by 17
Preventing Varicella-Zoster: Advances With the Recombinant Zoster Vaccine
Ilyas, S., & Chandrasekar, P. H. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa274 · Cited by 17
Kim, J. H., Diaz-Decaro, J. D., Jiang, N., Hwang, S., Choo, E. J., Co, M. M., Hastie, A., Hui, D. S. C., Irimajiri, J., Lee, J., et al. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1859321 · Cited by 17
Self-citationBurke, M., & Rowe, T. A. (2017) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2017.08.006 · Cited by 17
Xia, Y., Ye, X., Zhu, W., Ai, J., Shen, Y., Shi, Z., Cui, C., Yuan, Y., Zhu, D., & He, P. (2025) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2025.108005 · Cited by 16
Recombinant zoster vaccine is associated with a reduced risk of dementia
Rayens, E. A., Sy, L. S., Qian, L., Ackerson, B. K., Tubert, J. E., Luo, Y., Modha, P. P., Calderon, R., Chmielewski-Yee, E., Oraichi, D., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-69289-0 · Cited by 16
Bhatnagar, N., Kim, K., Jeeva, S., Park, B. R., Ko, E., Seong, B. L., & Kang, S. (2021) · Antiviral Research · doi:10.1016/j.antiviral.2021.105229 · Cited by 16
Therapeutic Implications of the Microbial Hypothesis of Mental Illness
Savitz, J. B., & Yolken, R. H. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_368 · Cited by 15
Esteban, A., Steiner, M., Castañeda-Estévez, E., Vázquez, C. A., Thiussard, I. J., Somodevilla, Á., Gracia-Martínez, M., Sánchez-Díaz, R., Yubero, C. G., Paredes-Romero, M. B., et al. (2023) · Vaccines · doi:10.3390/vaccines11101610 · Cited by 16
Pullen, R. H., Sassano, E. R., Agrawal, P., Escobar, J., Chehtane, M., Schanen, B. C., Drake, D. R., Luna, E., & Brennan, R. (2024) · The Journal of Immunology · doi:10.4049/jimmunol.2300185 · Cited by 16
Wang, J., Jin, P., Jin, H., Wang, Q., Zhu, F., & Li, J. (2024) · Vaccines · doi:10.3390/vaccines12080872 · Cited by 16
Pharmacotherapy Pearls in Rheumatology for the Care of Older Adult Patients
Betancourt, B. Y., Biehl, A. J., Katz, J. D., & Subedi, A. (2018) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2018.03.010 · Cited by 17
Humoral immunity to varicella zoster virus is altered in patients with rheumatoid arthritis
Krasselt, M., Baerwald, C., Liebert, U. G., & Seifert, O. (2019) · Clinical Rheumatology · doi:10.1007/s10067-019-04563-9 · Cited by 16
Görander, S., Honda‐Okubo, Y., Bäckström, M., Baldwin, J., Bergström, T. B., Petrovsky, N., & Liljeqvist, J. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.08.050 · Cited by 16
Liu, Y., Yu, L., Che, X., & Yan, M. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.804362 · Cited by 16
Survey of Physician Practices, Attitudes, and Knowledge Regarding Recombinant Zoster Vaccine
Hurley, L. P., O’Leary, S. T., Dooling, K. L., Anderson, T. C., Crane, L. A., Cataldi, J. R., Brtnikova, M., Beaty, B. L., Gorman, C., Guo, A., et al. (2022) · Journal of General Internal Medicine · doi:10.1007/s11606-022-07721-z · Cited by 16
Pettigrew, Z. J., Kim, M. H., & Becker‐Dreps, S. (2023) · Springer eBooks · doi:10.1007/978-3-031-29171-5_12 · Cited by 18
Patel, N. P., Vukmanovic‐Stejic, M., Suárez‐Fariñas, M., Chambers, E. S., Sandhu, D., Fuentes‐Duculan, J., Mabbott, N. A., Rustin, M. H. A., Krueger, J. G., & Akbar, A. N. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiy420 · Cited by 17
Herpes Zoster Eye Disease: New Ways to Combat an Old Foe?
Jeng, B. H. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2018.08.029 · Cited by 16
Ocran-Appiah, J. C., Boutry, C., Hervé, C., Soni, J., Schuind, A., Olsson, Å., Ahonen, A., Marta, A. N., Charles, A., Arya, M., et al. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.10.029 · Cited by 16
Self-citationHe, L., Sun, B., Guo, Y., Yan, K., Liu, D., Zang, Y., Jiang, C., Zhang, Y., & Kong, W. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108216 · Cited by 15
Callegaro, A., Burny, W., Hervé, C., Kim, J. H., Levin, M. J., Zahaf, T., Cunningham, A. L., & Didierlaurent, A. M. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab536 · Cited by 15
Self-citationDiagnostic Methods and Management Strategies of Herpes Simplex and Herpes Zoster Infections
Mehrmal, S., Mojica, R. E., Guo, A. M., & Missall, T. A. (2023) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2023.09.003 · Cited by 17
Ali, O., Dessart, C., & Parikh, R. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.02.035 · Cited by 15
Micheletto, C., Aliberti, S., Andreoni, M., Blasi, F., Marco, F. D., Matteo, R. D., Gabutti, G., Harari, S. A., Gentile, I., Parrella, R., et al. (2025) · Respiration · doi:10.1159/000544919 · Cited by 15
Metadata
- Authors
- Cunningham, A. L., Lal, H., Kovac, M., Chlibek, R., Hwang, S.-J., Díez-Domingo, J., Godeaux, O., Levin, M. J., McElhaney, J. E., Puig-Barberà, J., Vanden Abeele, C., Vesikari, T., Watanabe, D., Zahaf, T., Ahonen, A., Athan, E., Barba-Gomez, J. F., Campora, L., de Looze, F., Downey, H. J., Ghesquiere, W., Gorfinkel, I., Korhonen, T., Leung, E., McNeil, S. A., Oostvogels, L., Rombo, L., Smetana, J., Weckx, L., Yeo, W., & Heineman, T. C.
- Affiliations
- The University of Sydney (AU)
- Uppsala University (SE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-09-15
- Volume
- 375
- Issue
- 11
- Pages
- 1019-1032
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2519957152
- Cited by
- 1,070
- References
- 31
- Citations by year
- 2026: 96 · 2025: 124 · 2024: 107 · 2023: 97 · 2022: 91 · 2021: 120 · 2020: 94 · 2019: 117 · 2018: 138 · 2017: 75 · 2016: 11
- FWCI
- 106.61
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Online (University of Wollongong) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- Sanofi
- Novo Nordisk
- Astellas Pharma
- H. Lundbeck A/S
- Sanofi Pasteur
- Topics
- Health Sciences › Medicine › Infectious Diseases › Herpesvirus Infections and Treatments
- Health Sciences › Medicine › Epidemiology › Cytomegalovirus and herpesvirus research
- Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
- Keywords
- herpes zoster, postherpetic neuralgia, vaccine efficacy, older adults, AS01B adjuvant, vaccine safety, herpes zoster incidence, vaccine adverse events, immunosenescence, immunogenicity
- MeSH terms
- Aged, Aged, 80 and over, Double-Blind Method, Female, Herpes Zoster, Humans, Male, Middle Aged, Risk, Vaccines, Subunit, Neuralgia, Postherpetic, Herpes Zoster Vaccine, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
